FMS-like tyrosine kinase 3 (FLT3) inhibitors: Molecular docking and experimental studies

详细信息    查看全文

• 作者：Baratali Mashkani^a ; ^b ; ^{Baratali.Mashkani@uon.edu.au" class="auth_mail" title="E-mail the corresponding author} ; ^{mashkaniba@mums.ac.ir" class="auth_mail" title="E-mail the corresponding author} ; Mohammad Hossein Tanipour^a ; ^c ; ^{TanipourMH2@mums.ac.ir" class="auth_mail" title="E-mail the corresponding author} ; Mohammad Saadatmandzadeh^d ; Leonie K. Ashman^b ; ^{leonie.ashman@newcastle.edu.au" class="auth_mail" title="E-mail the corresponding author} ; Renate Griffith^e ; ^{r.griffith@unsw.edu.au" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Imatinib (PubChem CID ; 5291) ; Dasatinib (PubChem CID ; 3062316) ; Sunitinib (PubChem CID ; 5329102) ; PKC412 (PubChem CID ; 9829523) ; CEP701 (PubChem CID ; 126565)
• 刊名：European Journal of Pharmacology
• 出版年：2016
• 出版时间：5 April 2016
• 年：2016
• 卷：776
• 期：Complete
• 页码：156-166
• 全文大小：2075 K

文摘

Activating mutations in FMS-like tyrosine kinase 3 (FLT3) occur in 25% of acute lymphoid and 30% of acute myeloid leukaemia cases. Therefore, FLT3 is a potential therapeutic target for small molecule kinase inhibitors. In this study, protein-ligand interactions between FLT3 and kinase inhibitors (CEP701, PKC412, sunitinib, imatinib and dasatinib) were obtained through homology modelling and molecular docking. A cellular system for experimental testing of the inhibitors was also established by expressing wildtype and internal tandem duplication mutant FLT3 (FLT3-WT and FLT3-ITD) in FDC-P1 cells. Imatinib and dasatinib could not be docked into any of the FLT3 models, consistent with their lack of activity in the experimental assays. CEP701, PKC412 and sunitinib interacted with the ATP-binding pocket of FLT3, forming H-bonds with Cys694 and Glu692. Based on the EC₅₀ values in the cell proliferation assay, CEP701 was the most potent inhibitor; sunitinib and PKC412 were ranked second and third, respectively. Sunitinib was the most selective inhibitor, followed by PKC421 and CEP701. The potency of sunitinib and to a lesser extent CEP701 in inhibition of FLT3 autophosphorylation was lower than the cell proliferation inhibition, indicating that inhibition of FLT3 downstream proteins may contribute to the cellular effects. It was shown in this study that the docking procedure was able to differentiate FLT3 inhibitors from ineffective compounds. Additionally, interaction with the phosphate binding region in the ATP-binding pocket increased potency at the cost of selectivity. These findings can be applied in designing highly effective and selective inhibitors for FLT3 and other related kinases.